<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860416</url>
  </required_header>
  <id_info>
    <org_study_id>ELM-28</org_study_id>
    <nct_id>NCT02860416</nct_id>
  </id_info>
  <brief_title>Additional Post Hoc Analysis and Clinical Data Collection</brief_title>
  <acronym>BNA™</acronym>
  <official_title>Additional Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElMindA Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElMindA Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect additional Investigational cognitive tasks and
      additional clinical data for subjects tested with ElMindA's Brain Network Activation (BNA™).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To collect additional Investigational cognitive tasks and additional clinical data for
      subjects tested with ElMindA's Brain Network Activation (BNA™).

      The BNA™ technology was developed and is utilized by ElMindA Ltd. The (BNA™) Analysis System
      is cleared for use by qualified medical professionals for the post hoc statistical analysis
      of the human electroencephalogram (&quot;EEG&quot;), utilizing evoked response potentials (&quot;ERP').
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>engineering development according to clinical assessments</measure>
    <time_frame>2 years</time_frame>
    <description>The study is designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical assessments and BNA scores. The results are primarily intended for scientific inquiry and engineering development purposes.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Neurological Observations</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who completed a BNA test with the Auditory Oddball Task, from both genders, aged
        3-99 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed a BNA test in the past

          -  Able to speak, read and understand English sufficiently to understand the nature of
             the study, and to allow completion of all study assessments.

          -  Willingness to participate

        Exclusion Criteria:

          -  Significant Sensory deficit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Skopin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ElMindA Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark D Skopin, PhD</last_name>
    <phone>2248880060</phone>
    <phone_ext>111</phone_ext>
    <email>mark@elminda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ElMindA</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark D Skopin, PhD</last_name>
      <phone>224-888-0060</phone>
      <phone_ext>111</phone_ext>
      <email>Mark@elminda.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Group</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant E Duffy, BSc.</last_name>
      <phone>402-817-2244</phone>
      <email>GDuffy@premierpsych.com</email>
    </contact>
    <investigator>
      <last_name>Walter J Duffy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
